| NCI-affiliated firm |
Partnership |
Other Firm(s) |
Date of record |
| Molecular Imaging Research |
Partnership to expand luciferase reporter cancer cell lines for preclinical in vivo imaging |
Dana Farber Cancer Institute |
Dec-11 |
| BIND |
Joins Nanomedicines Alliance |
Nanomedicines Alliance: BIND, Cerulean Pharma, CytImmune, Eli Lilly, NanoCarrier, NanoViricides, Pfizer, Roche |
2012 |
| Liquidia Technologies |
Signs licensing deal with GlaxoSmithKline |
GSK |
Jun-12 |
| Liquidia Technologies |
Joins Nanomedicines Alliance |
Nanomedicines Alliance: BIND, Cerulean Pharma, CytImmune, Eli Lilly, NanoCarrier, NanoViricides, Pfizer, Roche |
Jun-12 |
| Leonardo Biosystems |
Signs collaboration deal with NanoMedical Systems for manufacturing scale up of Leonardo's drug delivery nanoparticles |
NanoMedical Systems |
Nov-11 |
| Forma Therapeutics |
Partnership with BoehrringerIngelheim ($65M up front; up to $815M) |
BoehrringerIngelheim |
2012 |
| Forma Therapeutics |
GENENTECH (ROCHE) acquires Forma's pre-clinical cancer program |
Genentech; Roche |
2011 |
| Forma Therapeutics |
Partnerships |
Novartis, Cubist Pharmaceuticals, Esai Pharmaceuticals, Experimental Therapeutics Centre (Singapore), TGen Drug Development (TD2) |
2012 |
| Foundation Medicine |
Partnership |
Novartis, Celgene and Johnson & Johnson Pharmaceutical Research & Development |
2013 |
| Integrated Diagnostics |
Partnership; Agilent will add blood-based early cancer detection to their diagnostics platform; Integrated Diagnostics will acquire several Agilent LC and MS machines |
Agilent |
Jan-12 |
| H3 Biomedicine |
Partnership |
Horizon Discovery |
Oct-12 |
| H3 Biomedicine |
Partnership/funding |
Esai Co. |
Dec-11 |
| H3 Biomedicine |
Partnership |
Compendia Bioscience; Life Technologies |
Feb-12 |
| MicroCHIPS, Inc. |
Received 13.4 million dollar round of investment funding led by Novartis Venture Fund |
Novartis |
Apr-07 |
| Xintek |
Forms joint venture with Siemens to develop nanotechnology-enabled multi-pixel X-Ray tubes |
Siemens |
Sep-07 |
